Laurus Labs Ltd Stock Price Today (NSE: LAURUSLABS)
Fundamental Score
Laurus Labs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Laurus Labs Ltd share price today is ₹1369.80, down 0.48% on NSE/BSE as of 17 June 2026. Laurus Labs Ltd (LAURUSLABS) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹55.57K (Cr). The 52-week high for LAURUSLABS share price is ₹1398.80 and the 52-week low is ₹641.05. At a P/E ratio of 81.25x, LAURUSLABS is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 7.45% and a debt-to-equity ratio of 0.46.
Laurus Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Laurus Labs Ltd share price chart: 22.98% return over the past month. 52-week high ₹1398.80, 52-week low ₹641.05.
Laurus Labs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1388.00 | ₹1390.70 | ₹1370.50 | ₹1382.60 | 23.56L (Cr) | |
| ₹1372.40 | ₹1398.80 | ₹1358.00 | ₹1388.40 | 29.97L (Cr) | |
| ₹1383.00 | ₹1393.40 | ₹1356.40 | ₹1362.00 | 17.76L (Cr) | |
| ₹1381.70 | ₹1381.70 | ₹1381.70 | ₹1381.70 | 0.00 (Cr) | |
| ₹1369.90 | ₹1391.50 | ₹1365.10 | ₹1381.70 | 13.11L (Cr) | |
| ₹1361.00 | ₹1376.90 | ₹1357.00 | ₹1373.90 | 17.54L (Cr) | |
| ₹1345.00 | ₹1363.90 | ₹1340.00 | ₹1356.30 | 16.32L (Cr) | |
| ₹1355.70 | ₹1355.70 | ₹1332.10 | ₹1343.50 | 16.99L (Cr) | |
| ₹1373.90 | ₹1373.90 | ₹1342.20 | ₹1351.00 | 20.57L (Cr) | |
| ₹1339.00 | ₹1363.40 | ₹1335.60 | ₹1361.10 | 21.04L (Cr) |
Laurus Labs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1372.40 | ₹1398.80 | ₹1358.00 | ₹1382.60 | +0.74% | |
| ₹1100.95 | ₹1393.40 | ₹1100.95 | ₹1362.00 | +23.71% | |
| ₹1020.10 | ₹1144.85 | ₹994.25 | ₹1100.95 | +7.93% | |
| ₹1030.00 | ₹1073.90 | ₹936.30 | ₹992.70 | -3.62% | |
| ₹918.85 | ₹1103.55 | ₹917.95 | ₹1075.80 | +17.08% | |
| ₹1108.00 | ₹1141.00 | ₹951.80 | ₹965.00 | -12.91% | |
| ₹1035.00 | ₹1119.00 | ₹985.90 | ₹1108.00 | +7.05% | |
| ₹957.95 | ₹1033.50 | ₹955.70 | ₹1031.35 | +7.66% | |
| ₹845.00 | ₹972.40 | ₹843.00 | ₹953.65 | +12.86% | |
| ₹856.75 | ₹944.00 | ₹823.10 | ₹841.80 | -1.74% | |
| ₹874.30 | ₹895.05 | ₹810.05 | ₹856.90 | -1.99% | |
| ₹730.00 | ₹922.50 | ₹721.05 | ₹874.35 | +19.77% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Laurus Labs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Laurus Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LAURUSLABS across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (24.27%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (882.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (35.12%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (14.42% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Interest Coverage (5.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹140.11 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 37.89%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
6 factors identified
Below-Average Return on Equity (7.45%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.15%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 81.25x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (4.38% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Low Promoter Commitment (27.59%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Laurus Labs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Laurus Labs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Laurus Labs LtdLaurus Labs Ltd...Selected✓ LAURUSLABS • 540222 | 45.6/100 | ₹1369.80₹1370 | ₹55569.57₹55569.57 | 81.25Average 81.3 Average | 7.45%Poor 7.45% Poor | 9.15%Poor 9.15% Poor | 0.46Excellent 0.5 Excellent | 4.56%Average 4.56% Average | 14.42%Good 14.42% Good | 0.12% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Laurus Labs Ltd PE Ratio History
Historical price-to-earnings ratio for LAURUSLABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹6.64 | ₹1108.00 | 166.9x |
| FY 2024 | ₹2.97 | ₹602.70 | 202.9x |
| FY 2023 | ₹14.64 | ₹430.20 | 29.4x |
| FY 2022 | ₹15.35 | ₹375.25 | 24.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Laurus Labs Ltd Dividend History
Annual cash dividends paid by LAURUSLABS — dividend yield 0.12%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹43.13 Cr |
| FY 2024 | ₹86.18 Cr |
| FY 2023 | ₹107.47 Cr |
| FY 2022 | ₹85.86 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Laurus Labs Ltd Quarterly Performance
Latest quarterly metrics for LAURUSLABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.12%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
882.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
14.42%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
4.56%
Compounded annual net profit growth over 5 years
Laurus Labs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LAURUSLABS — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Laurus Labs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Laurus Labs Ltd (LAURUSLABS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Laurus Labs Ltd
About LAURUSLABS (Laurus Labs Ltd)
Laurus Labs Ltd is a dynamic pharmaceutical company forging a path in the global healthcare landscape. With a strong foundation in API manufacturing, Laurus Labs has strategically ...expanded its capabilities to encompass finished dosage formulations, catering to a diverse range of therapeutic areas. This vertically integrated approach allows for greater control over the entire drug development and manufacturing process, ensuring quality and efficiency. Beyond its core API and formulation businesses, Laurus Labs is actively engaged in research and development, investing in cutting-edge technologies and innovative processes to drive future growth. They are emerging as a solutions provider for the pharmaceutical industry, focused on delivering value and making a difference in the lives of patients worldwide. The company's robust portfolio caters to key global health concerns. Laurus Labs develops APIs and formulations across therapeutic segments like anti-retrovirals, crucial in the fight against HIV/AIDS. In addition, they focus on addressing the growing prevalence of conditions like diabetes and cardiovascular diseases, while also developing solutions for respiratory ailments and ophthalmic disorders. Laurus Labs has also ventured into the complex field of oncology, and has added gastroenterology and hepatitis C therapeutic areas, demonstrating their commitment to providing solutions to a diverse spectrum of medical needs. This strategic diversification allows Laurus Labs to mitigate risk and capitalize on emerging opportunities in the pharmaceutical market. Beyond pharmaceuticals, Laurus Labs has expanded its portfolio, exploring opportunities in biotechnology. The company provides services tailored to support industries in the nutraceutical and dietary supplement segments. This includes developing solutions for alternative food applications, reflecting the company's commitment to innovation and diversification. By harnessing its biotechnology capabilities, Laurus Labs has broadened its market reach and expanded its scope to cater to the rapidly evolving needs of the health and wellness industry. This strategic move positions Laurus Labs at the forefront of innovation, enabling the company to capitalize on emerging opportunities and drive future growth.
Company Details
Key Leadership
Corporate Events
Latest News
LAURUSLABS Share Price: Frequently Asked Questions
What is the current share price of Laurus Labs Ltd?
Laurus Labs Ltd (LAURUSLABS) trades at ₹1369.80 on NSE and BSE. Market cap ₹55.57K (Cr). Educational data only.
What is the P/E ratio of Laurus Labs Ltd?
Laurus Labs Ltd has a P/E of 81.25x vs industry average 31.77x.
What is the Bull Run score for Laurus Labs Ltd?
Laurus Labs Ltd has a Bull Run score of 45.6/100 based on 25+ financial parameters.
Does Laurus Labs Ltd pay dividends?
Laurus Labs Ltd has a dividend yield of 0.12%. Past dividends don't guarantee future payments.
What is the ROE of Laurus Labs Ltd?
Laurus Labs Ltd has ROE of 7.45%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Laurus Labs Ltd?
Laurus Labs Ltd has debt-to-equity of 0.46.
Is Laurus Labs Ltd a good investment?
Bull Run gives Laurus Labs Ltd a score of 45.6/100. This is not investment advice — consult a SEBI-registered advisor.